Day: September 2, 2022

Frontline Ltd. (the “Company”) announces that its 2022 Annual General Meeting will be held on September 30, 2022. A copy of the Notice of Annual General Meeting and associated information including the Company’s Annual Report on Form 20-F for 2021 can be found on our website at www.frontline.bm and attached to this press release. September 2, 2022 The Board of DirectorsFrontline Ltd.Hamilton, Bermuda This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading ActAttachmentsFRO – Notice of Annual General Meeting 2022FRO – 2021 Annual Report on Form 20-F

London, September 2, 2022 CNH Industrial N.V. (NYSE: CNHI / MI: CNHI) today announces that John Lanaway has retired from the Company’s Board of Directors with immediate effect for health reasons. Mr. Lanaway has served on CNH Industrial’s Board, and that of its predecessor companies since his initial appointment in 2006. “I would like to sincerely thank John for his over 15 years of service as a member of CNH Industrial’s board. His wise counsel and keen financial oversight have been invaluable to the Board and his significant contributions to the Company will be his enduring legacy,” said Suzanne Heywood, Chair, CNH Industrial. “We are grateful for his fellowship and thankful for his service.” Karen Linehan has been appointed as Mr. Lanaway’s successor as Chair of the Audit Committee.   CNH Industrial (NYSE: CNHI / MI: CNHI) is a world-class...

THIS NEWS RELEASE CONSTITUTES A “DESIGNATED NEWS RELEASE” FOR THE PURPOSES OF THE COMPANY’S PROSPECTUS SUPPLEMENT DATED SEPTEMBER 2, 2022 TO ITS AMENDED AND RESTATED SHORT FORM BASE SHELF PROSPECTUS DATED JANUARY 4, 2022 VANCOUVER, British Columbia, Sept. 02, 2022 (GLOBE NEWSWIRE) — Hive Blockchain Technologies Ltd. (“HIVE” or the “Company”) (Nasdaq: HIVE; TSXV: HIVE; FSE: HBFA.F) is pleased to announce that it has entered into an at-the-market offering agreement (the “ATM Agreement”) with H.C. Wainwright & Co. (the “Agent”). At-the Market Offering Pursuant to the ATM Agreement, the Company and the Agent will implement an “at-the-market” equity offering program, under which the Agent may issue and sell from time to time such number of common shares of the Company (the “Common Shares”) having an aggregate offering price of...

Golden Ocean Group Limited (the “Company”) announces that its 2022 Annual General Meeting will be held on September 30, 2022. A copy of the Notice of Annual General Meeting and associated information including the Company’s Consolidated Financial Statements on Form 20-F for 2021 can be found on our website at www.goldenocean.bm and in the links below. September 2, 2022 The Board of DirectorsGolden Ocean Group LimitedHamilton, Bermuda This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act    AttachmentsGOGL – Notice of Annual General Meeting 2022GOGL – 2021 Form 20-F

Montrouge, France, September 2, 2022 DBV Technologies to Present at Upcoming Investor Conferences DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that Daniel Tassé, Chief Executive Officer, DBV Technologies, will participate in upcoming investor conferences in September. Wells Fargo Healthcare ConferenceSeptember 7 – 9, 2022 | In-Person Conference | Boston, MADaniel Tassé will be on-site in Boston on Thursday, September 8, 2022 to participate in a fireside chat at 4:20 p.m. ET. H.C. Wainwright 24rd Annual Global Investment ConferenceSeptember 12 – 14, 2022 | Hybrid In-Person and Virtual Conference | New York, NYDaniel Tassé will be on-site in New York on Monday, September 12, 2022 for a company presentation at 11:00 a.m. ET. A webcast of each...

Millicom (Tigo) to Present at the 2022 Goldman Sachs Communacopia + Technology Conference Luxembourg, September 2, 2022 – Millicom International Cellular SA (“Millicom”) announces that Millicom’s Chief Executive Officer, Mauricio Ramos, will be presenting at the Goldman Sachs Communacopia + Technology Conference on Tuesday, September 13, 2022. The live event will take place in San Francisco and is expected to begin at approximately 7:30 am local time (10:30 am Miami / 4:30 pm Stockholm). A live webcast and replay of the presentation will be available at millicom.com/investors or at the following link. -END- For further information, please contactPress:Yocasta Valdez, Sr. Manager Digital Media & Communicationspress@millicom.com Investors:Michel Morin, VP Investor RelationsSarah Inmon, Director Investor Relationsinvestors@millicom.com ...

NEW YORK, Sept. 02, 2022 (GLOBE NEWSWIRE) — Mobiquity Technologies, Inc. (NASDAQ: MOBQ) (the “Company”), announced that, as previously reported in the Company’s Quarterly Report on Form 10-Q for the period ended June 30, 2022, the Company and Don (Trey) Barrett III resolved a dispute regarding the employment separation of Mr. Barrett from the company. Among other things, they agreed that that Mr. Barrett’s employment separation from the company on March 17, 2022 (previously reported in the Company’s Current Report on Form 8-K filed on March 23, 2022) is deemed mutual and not for cause, and the Company will not incur any material early termination penalties. About Mobiquity TechnologiesMobiquity Technologies, Inc. is a next-generation, Platform-as-a-Service (PaaS) company for data and advertising. The Company maintains one of the...

First subject vaccinated in Phase 3 clinical trial evaluating potential of the VLP-based candidate, ABNCoV2 as a booster COVID-19 vaccine Trial will assess non-inferiority of ABNCoV2 compared to Comirnaty® in terms of neutralizing antibodies against the SARS-CoV-2 (Wuhan wild type) as the primary endpoint, and other variants of concern as secondary endpointsCOPENHAGEN, Denmark, September 2, 2022 – Bavarian Nordic A/S (OMX: BAVA) announced today the dosing of the first subject in the Phase 3 clinical trial of ABNCoV2, a VLP-based, non-adjuvanted COVID-19 booster vaccine candidate. The double-blind, controlled Phase 3 clinical trial will enroll approximately 4,000 adult subjects who either previously completed primary vaccination or have already received one booster dose of a licensed COVID-19 vaccine. The trial consists of two groups....